Literature DB >> 30141990

Fibrolamellar Carcinoma: A Concise Review.

Chun-Chieh Lin, Hui-Min Yang1.   

Abstract

Fibrolamellar carcinoma is a rare primary hepatocellular malignancy arising in noncirrhotic livers of young individuals. Patients commonly present with a large solitary liver mass and nonspecific symptoms. Characteristic histologic features include large polygonal cells with oncocytic cytoplasm and prominent nucleoli separated into trabeculae and cords by dense parallel bands of collagen. Important differential diagnoses include classical hepatocellular carcinoma and intrahepatic cholangiocarcinoma, which may be distinguished by a judicious panel of immunohistochemical studies, including cytokeratin 7, CD68, and hepatocyte paraffin 1 (HepPar-1). In addition, fibrolamellar carcinomas are characterized by activation of protein kinase A. Prognosis of fibrolamellar carcinoma is similar to classical hepatocellular carcinoma occurring in the absence of liver cirrhosis and is strongly correlated with tumor resectability. Other treatment options include liver transplant, chemotherapy, and hepatic artery embolization. In this article, we review the clinical features, gross and microscopic pathology, molecular genetics, differential diagnosis, treatment, and prognosis of this rare and interesting tumor.

Entities:  

Mesh:

Year:  2018        PMID: 30141990     DOI: 10.5858/arpa.2017-0083-RS

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study.

Authors:  Tomoki Sempokuya; Arnold Forlemu; Muaataz Azawi; Krixie Silangcruz; Nathalie Khoury; Jihyun Ma; Linda L Wong
Journal:  World J Clin Oncol       Date:  2022-05-24

2.  Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma.

Authors:  Xiaoyuan Chen; Yiwei Lu; Xiaoli Shi; Guoyong Han; Long Zhang; Chuangye Ni; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

3.  Human liver organoids for disease modeling of fibrolamellar carcinoma.

Authors:  Nicole J C Narayan; David Requena; Gadi Lalazar; Lavoisier Ramos-Espiritu; Denise Ng; Solomon Levin; Bassem Shebl; Ruisi Wang; William J Hammond; James A Saltsman; Helmuth Gehart; Michael S Torbenson; Hans Clevers; Michael P LaQuaglia; Sanford M Simon
Journal:  Stem Cell Reports       Date:  2022-07-07       Impact factor: 7.294

4.  Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation.

Authors:  Takaaki Hasegawa; Hiroaki Kuroda; Noriaki Sakakura; Yozo Sato; Shohei Chatani; Shinichi Murata; Hidekazu Yamaura; Takeo Nakada; Yuko Oya; Yoshitaka Inaba
Journal:  Thorac Cancer       Date:  2021-06-09       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.